On a large-scale RNAseq profiling of 769 GBM patients from five independent datasets, the score evaluation, defined as GBM-associated TIME immune cell infiltration (GTMEI) score, of more than 20 immune cell marker genes, including Thy-1 CD4, were analyzed in patients with different MGMT methylation status to define prognostic classes [52] and/or response to treatment [53]. This evidence concerns the gene CD4 and glioblastoma.